DARUNAVIR

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H37N3O7S
Molecular Weight	547.664
Optical Activity	( - )
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC3=CC=CC=C3)[C@H](O)CN(CC(C)C)S(=O)(=O)C4=CC=C(N)C=C4

InChI

InChIKey=CJBJHOAVZSMMDJ-HEXNFIEUSA-N

InChI=1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23708741 | http://adisinsight.springer.com/drugs/800016726

Darunavir (trade name Prezista) is an orally active bis-furan-sulfonamide inhibitor of human immunodeficiency virus (HIV-1) protease. Darunavir was developed by Tibotec Pharmaceuticals (now Janssen R&D Ireland). Darunavir is indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. The drug is co-administered with low-dose ritonavir and other anti-HIV agents. It is the only antiretroviral that has been registered at two different doses, 800/100 mg once-daily or 600/100 mg twice-daily, allowing its administration throughout the entire course of HIV disease, from naive subjects without any HIV-1 resistance to heavily treatment-experienced subjects with widespread triple-class family resistance.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus type 1 protease 35 Target ID: CHEMBL243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15479840	Inhibitor 8297		4.5 pM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 151 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	Primary		Approved 8429	PREZISTA Approved Use PREZISTA is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult patients. PREZISTA is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents. Launch Date 2006

C_max

Value	Dose	Co-administered	Analyte	Population
5272 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21926632/	800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Ritonavir	Ritonavir	DARUNAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
93026 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Ritonavir	Ritonavir	DARUNAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
124698 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Ritonavir	Ritonavir	DARUNAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
57055 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21926632/	800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Ritonavir	Ritonavir	DARUNAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
126377 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Ritonavir	Ritonavir	DARUNAVIR plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
15 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Ritonavir	Ritonavir	DARUNAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Ritonavir	Ritonavir	DARUNAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	800 mg 1 times / day steady-state, oral dose: 800 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Ritonavir	Ritonavir	DARUNAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Ritonavir	Ritonavir	DARUNAVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://pubmed.ncbi.nlm.nih.gov/20010070 Page: p.227	unhealthy, 43 n = 127 Health Status: unhealthy Condition: HIV-1 infection Age Group: 43 Sex: M+F Population Size: 127 Sources: https://pubmed.ncbi.nlm.nih.gov/20010070 Page: p.227	Disc. AE: Headache, Gastrointestinal disorder NOS... AEs leading to discontinuation/dose reduction: Headache (grade 3, 0.79%) Gastrointestinal disorder NOS (5.51%) Sources: https://pubmed.ncbi.nlm.nih.gov/20010070 Page: p.227
3200 mg single, oral Overdose Dose: 3200 mg Route: oral Route: single Dose: 3200 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.22	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.22	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.22
800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	Disc. AE: Drug-induced hepatitis, Hepatitis acute... AEs leading to discontinuation/dose reduction: Drug-induced hepatitis Hepatitis acute Cytolytic hepatitis Reaction skin (grade 1-3) Stevens-Johnson syndrome Toxic epidermal necrolysis Diabetes mellitus Hyperglycemia Fat redistribution Fat tissue increased Immune reconstitution syndrome Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.8	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.8	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (grade 1-2, 0.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.8

AEs

AE	Significance	Dose	Population
Gastrointestinal disorder NOS	5.51% Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://pubmed.ncbi.nlm.nih.gov/20010070 Page: p.227	unhealthy, 43 n = 127 Health Status: unhealthy Condition: HIV-1 infection Age Group: 43 Sex: M+F Population Size: 127 Sources: https://pubmed.ncbi.nlm.nih.gov/20010070 Page: p.227
Headache	grade 3, 0.79% Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://pubmed.ncbi.nlm.nih.gov/20010070 Page: p.227	unhealthy, 43 n = 127 Health Status: unhealthy Condition: HIV-1 infection Age Group: 43 Sex: M+F Population Size: 127 Sources: https://pubmed.ncbi.nlm.nih.gov/20010070 Page: p.227
Cytolytic hepatitis	Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Diabetes mellitus	Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Drug-induced hepatitis	Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Fat redistribution	Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Fat tissue increased	Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Hepatitis acute	Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Hyperglycemia	Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Immune reconstitution syndrome	Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Stevens-Johnson syndrome	Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Toxic epidermal necrolysis	Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Reaction skin	grade 1-3 Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.1
Rash	grade 1-2, 0.5% Disc. AE	800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Co-administed with:: ritonavir, oral(100 mg; qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.8	unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf Page: p.8

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:367163	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:367163
ChemicalBook	CB51176244	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51176244
MolPort	MolPort-003-846-141	https://www.molport.com/shop/molecule-link/MolPort-003-846-141
ZINC	ZINC000003955219	http://zinc15.docking.org/substances/ZINC000003955219
eMolecules	35833368	https://www.emolecules.com/cgi-bin/more?vid=35833368
eMolecules	36557635	https://www.emolecules.com/cgi-bin/more?vid=36557635

PubMed

Title	Date	PubMed
High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.	2004 Apr 23	15066436
Anti-HIV agents. What the future holds for TMC114.	2005 Aug-Sep	17219656
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.	2005 Jun	15917527
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.	2005 Jun 10	15905675
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.	2005 Mar 24	15771440
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.	2005 Mar 24	15771427
New protease inhibitor TMC-114. Preliminary 24-week late breaker results of the phase II trial.	2005 Mar-Apr	15828108
Meeting notes from the 3rd IAS Conference. New drugs.	2005 Oct	16276591
Report from the 13th retrovirus conference. New data on TMC114 and TMC125.	2006 Apr	16718876
FDA approves new PI.	2006 Jun	17233103
Drug interactions. Interactions with TMC114 and TMC125.	2006 Jun-Jul	17211920
XVI International AIDS Conference: Part 2.	2006 Nov	17152645
The latest in antiretroviral therapy.	2006 Oct	17160151
Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of hiv protease inhibitors that combat drug resistance.	2006 Sep	16927344
Darunavir (Prezista) for HIV infection.	2006 Sep 11	16977286
New HIV treatment.	2006 Sep-Oct	17326304
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.	2007	17713162
Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.	2007	17596110
Antiretroviral treatment of HIV infection: Swedish recommendations 2007.	2007	17577810
Key reports from the XV International HIV Drug Resistance Workshop 2006.	2007	17503758
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.	2007 Apr	17389557
Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.	2007 Apr 1	17243183
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.	2007 Apr 7	17416261
Darunavir: promising initial results.	2007 Apr 7	17416241
Darunavir: a second-generation protease inhibitor.	2007 Aug 1	17646561
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.	2007 Feb 19	17301557
48-week study results show DRV's staying power.	2007 Jan	17523243
Anti-HIV agents. Darunavir and some antidepressants.	2007 Jan	17390480
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.	2007 Jul 11	17589191
No patient left behind--better treatments for resistant HIV infection.	2007 Jul 7	17617250
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.	2007 Jun	17371811
Prezista gets EU approval.	2007 Mar	17428190
Editorial comment: impact of darunavir for salvage therapy.	2007 Mar	17396333
Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance.	2007 Mar	17396332
Tibotec and Aspen collaborate on Prezista.	2007 May	17546795
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.	2007 May	17461851
Analysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patients.	2007 May-Jun	17621459
Predicting HIV care costs using CD4 counts from clinical trials.	2007 Sep	17803366
Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen.	2007 Sep	17641132
Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.	2007 Winter	17405221

Patents

Sample Use Guides

In Vivo Use Guide

Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (two 400 mg tablets) taken with ritonavir 100 mg once daily and with food. Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food. Pediatric patients (3 to less than 18 years of age and weighing at least 10 kg): dosage of PREZISTA and ritonavir is based on body weight and should not exceed the treatmentexperienced adult dose. Do not use once daily dosing in pediatric patients. PREZISTA should be taken with ritonavir twice daily and with food.

Route of Administration: Oral

In Vitro Use Guide

Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human peripheral blood mononuclear cells and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to 5.0 ng/mL). Darunavir demonstrates antiviral activity in cell culture against a broad panel of HIV-1 group M (A, B, C, D, E, F, G), and group O primary isolates with EC50 values ranging from less than 0.1 to 4.3 nM.

Name

Type

Language

DARUNAVIR

Official Name

English

Darunavir [WHO-DD]

Common Name

English

(3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(ISOBUTYL)AMINO)-1-BENZYL-2-HYDROXYPROPYL)CARBAMATE

Common Name

English

((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-CARBAMIC ACID (3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ESTER

Common Name

English

Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester

Systematic Name

English

DARUNAVIR [MART.]

Common Name

English

(3R,3AS,6AR)-HEXAHYDROFURO(2,3-B)FURAN-3-YL ((2S,3R)-4-((4-AMINO-N-ISOBUTYLPHENYL)SULFONAMIDO)-3-HYDROXY-1-PHENYLBUTAN-2-YL)CARBAMATE

Systematic Name

English

TMC114

Code

English

(-)-DARUNAVIR

Common Name

English

DARUNAVIR [USAN]

Common Name

English

DARUNAVIR [ORANGE BOOK]

Common Name

English

darunavir [INN]

Common Name

English

DRV

Common Name

English

DARUNAVIR [MI]

Common Name

English

DARUNAVIR [EMA EPAR]

Common Name

English

TMC-41629

Code

English

DARUNAVIR [HSDB]

Common Name

English

TMC-114

Code

English

DARUNAVIR [VANDF]

Common Name

English

UIC-94017

Code

English

TMC 114

Code

English

Classification Tree Code System Code

WHO-ATC

J05AE10